Differential Reactivity of Human Mammary Artery and Saphenous Vein to Prostaglandin E(2) : Implication for Cardiovascular Grafts
Overview
Affiliations
Background And Purpose: Human internal mammary arteries (IMA) and saphenous veins (SV) are frequently used for coronary artery bypass graft surgery. Intra- and postoperatively, the bypass grafts are exposed to inflammatory conditions, under which there is a striking increase in the synthesis of prostaglandin E(2) (PGE(2) ). In this context, the physiological response of these vascular grafts to PGE(2) is highly relevant. The aim of this study was thus to characterize the PGE(2) receptor subtypes (EP(1) , EP(2) , EP(3) or EP(4) ) involved in modulation of the vascular tone in these two vessels.
Experimental Approach: Rings of IMA and SV were prepared from 48 patients. The rings were mounted in organ baths for isometric recording of tension, and a pharmacological study was performed, together with associated reverse transcriptase PCR and immunohistochemistry experiments.
Key Results: PGE(2) induced contractions of IMA (E(max) = 1.43 ± 0.20 g; pEC(50) = 7.50 ± 0.10); contractions were also observed with the EP(3) receptor agonists, sulprostone, 17-phenyl-PGE(2) , misoprostol or ONO-AE-248. In contrast, PGE(2) induced relaxation of the precontracted SV (E(max) =-0.22 ± 0.02 g; pEC(50) = 7.14 ± 0.09), as did the EP(4) receptor agonist, ONO-AE1-329. These results were confirmed by the use of selective EP receptor antagonists (GW627368X, L-826266, ONO-8713, SC-51322) and by molecular biology and immunostaining.
Conclusions And Implications: PGE(2) induced potent and opposite effects on the human vascular segments used for grafting, namely vasoconstriction of the IMA and vasodilatation of the SV via EP(3) and EP(4) receptors respectively. These observations suggest that EP(3) and EP(4) receptors could constitute therapeutic targets to increase vascular graft patency.
Dashwood M, Celik Z, Topal G Front Physiol. 2025; 16:1539102.
PMID: 39958693 PMC: 11825516. DOI: 10.3389/fphys.2025.1539102.
Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis.
Lubrano V, Ndreu R, Balzan S Int J Mol Sci. 2023; 24(2).
PMID: 36675152 PMC: 9863938. DOI: 10.3390/ijms24021637.
Malheiros J, Simoes D, Antunes P, Figueirinha A, Cotrim M, Fonseca D Pharmaceuticals (Basel). 2022; 15(5).
PMID: 35631463 PMC: 9143967. DOI: 10.3390/ph15050638.
Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease.
Zhou Y, Khan H, Xiao J, Cheang W Int J Mol Sci. 2021; 22(21).
PMID: 34769460 PMC: 8584625. DOI: 10.3390/ijms222112029.
Aringer I, Artinger K, Schabhuttl C, Barnthaler T, Mooslechner A, Kirsch A J Clin Med. 2021; 10(4).
PMID: 33670614 PMC: 7922874. DOI: 10.3390/jcm10040832.